Ayala Pharmaceuticals Inc (ADXS)

[cab033]

It's nice to see the institutions continuing to add small amounts to their holdings but did you notice the 2 largest changes in holdings during this past quarter in the open market?

A complete liquidation of all ADXS shares by Pictet Asset Management Ltd. All 1,428,619 shares valued at roughly $15MM. Their last reported 13F filing for Q3 2016 included $26,586,093,000 in managed 13F securities.

The next largest change in holdings was a complete liquidation of all ADXS shares by Orbimed Advisors. All 445,400 shares valued at roughly $4.5MM. Their last reported 13F filing for Q3 2016 included $8,780,843,000 in managed 13F securities.

Fidelity did add 1.3MM shares but it is believed that was the direct placement that took place after the Amgen deal.

The open market saw more selling than buying during the Q3 2016 with an increase of 1.2MM shares shorted. That is why if you look at the 3 month chart for the Q it trends down the entire quarter. Until more buying pressure starts to occur (or we get a new CEO) this stock will continue to trade the exact same way it always has. Small pops followed by sustained sell offs. Nothing to look forward to for at least another quarter or 2, possibly longer if DO misses deadlines or any additional set backs occur.